Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pentoxifylline vs Probiotics for NEC in Preterm Neonates
NCT06422000Phase 3Completed
- Sponsor
- Tanta University
- Start
- Jun 2022
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of pentoxifylline in necrotizing enterocolitis (NEC) (3 arms), sponsored by Tanta University. Primary endpoints: Mortality rate at 2 months, complications and side effects at 2 months and 1 more. Started Jun 2022; status: completed.
02
Drugs
pentoxifylline
03
Conditions
necrotizing enterocolitis (NEC)
Beyond the preview
Go deeper on NCT06422000.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06422000.